Craft

Evofem Biosciences

Stock Price

$0

2024-10-29

Market Capitalization

$1.2 M

2024-10-29

Revenue

$20.2 M

FY, 2025

Evofem Biosciences Summary

Company Summary

Overview
Evofem Biosciences, a clinical-stage biopharmaceutical company, develops and commercializes women’s sexual and reproductive health products. It offers Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The Сompany is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. 
Type
Public
Status
Active
Founded
2007
HQ
San Diego, CA, US | view all locations
Website
http://www.evofem.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Saundra Pelletier

    Saundra Pelletier, Chief Executive Officer & interim Chair of the Board

  • Ivy Zhang

    Ivy Zhang, Chief Financial Officer and Secretary

  • Ellen Thomas
  • Kim Kamdar, Director

    LocationsView all

    1 location detected

    • San Diego, CA HQ

      United States

      12400 High Bluff Dr

    Evofem Biosciences Financials

    Summary Financials

    Revenue (FY, 2025)
    $20.2M
    Gross profit (FY, 2025)
    $15.6M
    Net income (FY, 2025)
    $391.0K
    Cash (FY, 2025)
    $578.0K
    EBIT (FY, 2025)
    $3.4M
    Enterprise value
    $1.1M

    Footer menu